Viral hemorrhagic fever: Difference between revisions

Jump to navigation Jump to search
Line 29: Line 29:
The Arenaviridae include the viruses responsible for [[Lassa fever]] and [[Argentine hemorrhagic fever|Argentine]], [[Bolivian hemorrhagic fever|Bolivian]], and [[Venezuelan hemorrhagic fever]]s. The Bunyaviridae include the members of the ''[[Hantavirus]]'' genus that cause [[hemorrhagic fever with renal syndrome]] (HFRS), the [[Crimean-Congo hemorrhagic fever]] (CCHF) virus from the ''[[Nairovirus]]'' genus, and the [[Rift Valley fever]] (RVF) virus from the ''[[Phlebovirus]]'' genus. The Filoviridae include [[Ebola virus|Ebola]] and [[Marburg virus]]es. Finally, the Flaviviridae include [[dengue]], [[yellow fever]], and two viruses in the [[tick-borne encephalitis]] group that cause VHF: [[Omsk hemorrhagic fever]] virus and [[Kyasanur Forest disease]] virus.
The Arenaviridae include the viruses responsible for [[Lassa fever]] and [[Argentine hemorrhagic fever|Argentine]], [[Bolivian hemorrhagic fever|Bolivian]], and [[Venezuelan hemorrhagic fever]]s. The Bunyaviridae include the members of the ''[[Hantavirus]]'' genus that cause [[hemorrhagic fever with renal syndrome]] (HFRS), the [[Crimean-Congo hemorrhagic fever]] (CCHF) virus from the ''[[Nairovirus]]'' genus, and the [[Rift Valley fever]] (RVF) virus from the ''[[Phlebovirus]]'' genus. The Filoviridae include [[Ebola virus|Ebola]] and [[Marburg virus]]es. Finally, the Flaviviridae include [[dengue]], [[yellow fever]], and two viruses in the [[tick-borne encephalitis]] group that cause VHF: [[Omsk hemorrhagic fever]] virus and [[Kyasanur Forest disease]] virus.


    Normal  0              false  false  false      EN-US  X-NONE  X-NONE                                                    MicrosoftInternetExplorer4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    == Risk Factors ==
== Risk Factors ==
VHF should be suspected in febrile persons who, within 3 weeks before onset of fever, have either 1) traveled in the specific local area of a country where VHF has recently occurred; 2) had direct unprotected contact with blood, other body fluids, secretions, or excretions of a person or animal with VHF; or 3) had a possible exposure when working in a laboratory that handles hemorrhagic fever viruses. The likelihood of acquiring VHF is considered low in persons who do not meet any of these criteria. Even following travel to areas where VHF has occurred, persons with fever are more likely to have infectious diseases other than VHF (e.g., common respiratory viruses, endemic infections such as malaria or typhoid fever). Clinicians should promptly evaluate and treat patients for these more common infections while awaiting confirmation of a VHF diagnosis.
VHF should be suspected in febrile persons who, within 3 weeks before onset of fever, have either 1) traveled in the specific local area of a country where VHF has recently occurred; 2) had direct unprotected contact with blood, other body fluids, secretions, or excretions of a person or animal with VHF; or 3) had a possible exposure when working in a laboratory that handles hemorrhagic fever viruses. The likelihood of acquiring VHF is considered low in persons who do not meet any of these criteria. Even following travel to areas where VHF has occurred, persons with fever are more likely to have infectious diseases other than VHF (e.g., common respiratory viruses, endemic infections such as malaria or typhoid fever). Clinicians should promptly evaluate and treat patients for these more common infections while awaiting confirmation of a VHF diagnosis.


Line 38: Line 38:
===== References =====
===== References =====
http://www.cdc.gov/ncidod/dhqp/bp_vhf_interimGuidance.html
http://www.cdc.gov/ncidod/dhqp/bp_vhf_interimGuidance.html
== Pathophysiology==
VHFs are caused by viruses of four distinct families: arenaviruses, filoviruses, bunyaviruses, and flaviviruses. Each of these families share a number of features:
*They are all RNA viruses, and all are covered, or enveloped, in a fatty (lipid) coating.
*Their survival is dependent on an animal or insect host, called the natural reservoir.
*The viruses are geographically restricted to the areas where their host species live.
*Humans are not the natural reservoir for any of these viruses. Humans are infected when they come into contact with infected hosts. However, with some viruses, after the accidental transmission from the host, humans can transmit the virus to one another.
*Human cases or outbreaks of hemorrhagic fevers caused by these viruses occur sporadically and irregularly. The occurrence of outbreaks cannot be easily predicted.
*With a few noteworthy exceptions, there is no cure or established drug treatment for VHFs.
*In rare cases, other viral and bacterial infections can cause a hemorrhagic fever; scrub typhus is a good example.
Viruses associated with most VHFs are zoonotic. This means that these viruses naturally reside in an animal reservoir host or arthropod vector. They are totally dependent on their hosts for replication and overall survival. For the most part, rodents and arthropods are the main reservoirs for viruses causing VHFs. The multimammate rat, cotton rat, deer mouse, house mouse, and other field rodents are examples of reservoir hosts. Arthropod ticks and mosquitoes serve as vectors for some of the illnesses. However, the hosts of some viruses remain unknown -- Ebola and Marburg viruses are well-known examples.
''How are hemorrhagic fever viruses transmitted?''
Viruses causing hemorrhagic fever are initially transmitted to humans when the activities of infected reservoir hosts or vectors and humans overlap. The viruses carried in rodent reservoirs are transmitted when humans have contact with urine, fecal matter, saliva, or other body excretions from infected rodents. The viruses associated with arthropod vectors are spread most often when the vector mosquito or tick bites a human, or when a human crushes a tick. However, some of these vectors may spread virus to animals, livestock, for example. Humans then become infected when they care for or slaughter the animals.
Some viruses that cause hemorrhagic fever can spread from one person to another, once an initial person has become infected. Ebola, Marburg, Lassa and Crimean-Congo hemorrhagic fever viruses are examples. This type of secondary transmission of the virus can occur directly, through close contact with infected people or their body fluids. It can also occur indirectly, through contact with objects contaminated with infected body fluids. For example, contaminated syringes and needles have played an important role in spreading infection in outbreaks of Ebola hemorrhagic fever and Lassa fever.
===== References =====
http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/vhf.htm


==Clinical and treatment aspects==
==Clinical and treatment aspects==

Revision as of 13:18, 9 January 2009

Template:DiseaseDisorder infobox

WikiDoc Resources for Viral hemorrhagic fever

Articles

Most recent articles on Viral hemorrhagic fever

Most cited articles on Viral hemorrhagic fever

Review articles on Viral hemorrhagic fever

Articles on Viral hemorrhagic fever in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Viral hemorrhagic fever

Images of Viral hemorrhagic fever

Photos of Viral hemorrhagic fever

Podcasts & MP3s on Viral hemorrhagic fever

Videos on Viral hemorrhagic fever

Evidence Based Medicine

Cochrane Collaboration on Viral hemorrhagic fever

Bandolier on Viral hemorrhagic fever

TRIP on Viral hemorrhagic fever

Clinical Trials

Ongoing Trials on Viral hemorrhagic fever at Clinical Trials.gov

Trial results on Viral hemorrhagic fever

Clinical Trials on Viral hemorrhagic fever at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Viral hemorrhagic fever

NICE Guidance on Viral hemorrhagic fever

NHS PRODIGY Guidance

FDA on Viral hemorrhagic fever

CDC on Viral hemorrhagic fever

Books

Books on Viral hemorrhagic fever

News

Viral hemorrhagic fever in the news

Be alerted to news on Viral hemorrhagic fever

News trends on Viral hemorrhagic fever

Commentary

Blogs on Viral hemorrhagic fever

Definitions

Definitions of Viral hemorrhagic fever

Patient Resources / Community

Patient resources on Viral hemorrhagic fever

Discussion groups on Viral hemorrhagic fever

Patient Handouts on Viral hemorrhagic fever

Directions to Hospitals Treating Viral hemorrhagic fever

Risk calculators and risk factors for Viral hemorrhagic fever

Healthcare Provider Resources

Symptoms of Viral hemorrhagic fever

Causes & Risk Factors for Viral hemorrhagic fever

Diagnostic studies for Viral hemorrhagic fever

Treatment of Viral hemorrhagic fever

Continuing Medical Education (CME)

CME Programs on Viral hemorrhagic fever

International

Viral hemorrhagic fever en Espanol

Viral hemorrhagic fever en Francais

Business

Viral hemorrhagic fever in the Marketplace

Patents on Viral hemorrhagic fever

Experimental / Informatics

List of terms related to Viral hemorrhagic fever

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

The viral hemorrhagic fevers (VHFs) are a diverse group of animal and human illnesses that are caused by five distinct families of RNA viruses: the Arenaviridae, Filoviridae, Bunyaviridae, Togaviridae, and Flaviviridae. All types of VHF are characterized by fever and bleeding disorders and all can progress to high fever, shock and death in extreme cases. Some of the VHF agents cause relatively mild illnesses, such as the Scandinavian nephropathia epidemica, whilst others, such as the African Ebola virus, can cause severe, life-threatening disease.

Also known as:

References

http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/vhf.htm

http://www.cdc.gov/ncidod/diseases/virlfvr/virlfvr.htm

Etiologic agents

The Arenaviridae include the viruses responsible for Lassa fever and Argentine, Bolivian, and Venezuelan hemorrhagic fevers. The Bunyaviridae include the members of the Hantavirus genus that cause hemorrhagic fever with renal syndrome (HFRS), the Crimean-Congo hemorrhagic fever (CCHF) virus from the Nairovirus genus, and the Rift Valley fever (RVF) virus from the Phlebovirus genus. The Filoviridae include Ebola and Marburg viruses. Finally, the Flaviviridae include dengue, yellow fever, and two viruses in the tick-borne encephalitis group that cause VHF: Omsk hemorrhagic fever virus and Kyasanur Forest disease virus.

Risk Factors

VHF should be suspected in febrile persons who, within 3 weeks before onset of fever, have either 1) traveled in the specific local area of a country where VHF has recently occurred; 2) had direct unprotected contact with blood, other body fluids, secretions, or excretions of a person or animal with VHF; or 3) had a possible exposure when working in a laboratory that handles hemorrhagic fever viruses. The likelihood of acquiring VHF is considered low in persons who do not meet any of these criteria. Even following travel to areas where VHF has occurred, persons with fever are more likely to have infectious diseases other than VHF (e.g., common respiratory viruses, endemic infections such as malaria or typhoid fever). Clinicians should promptly evaluate and treat patients for these more common infections while awaiting confirmation of a VHF diagnosis.

In Africa, transmission of VHF in healthcare settings has been associated with reuse of contaminated needles and syringes and with provision of patient care without appropriate barrier precautions to prevent exposure to virus-containing blood and other body fluids (including vomitus, urine, and stool). The transmission risks associated with various body fluids have not been well defined because most caregivers who have acquired infection had contacts with multiple fluids.

The risk for person-to-person transmission of hemorrhagic fever viruses is greatest during the latter stages of illness when virus loads are highest; latter stages of illness are characterized by vomiting, diarrhea, shock, and, in less than half of infected patients, hemorrhage. No VHF infection has been reported in persons whose contact with an infected person occurred only during the incubation period (i.e., before onset of fever). The incubation period for VHF ranges from 2 days to 3 weeks, depending on the viral agent. There are reports of Ebola virus transmission occurring within a few days after onset of fever; however, the presence of other symptoms in the source patients and the level of exposure to body fluids among secondary cases are unknown in these instances (CDC, unpublished data, 1995). In studies involving three monkeys experimentally infected with Ebola virus (Reston strain), fever and other systemic signs of illness preceded detection of infectious virus in the animals’ pharynx by 2-4 days, in the conjunctivae and on anal swabs by 5-6 days, and in the nares by 5-10 days.

References

http://www.cdc.gov/ncidod/dhqp/bp_vhf_interimGuidance.html

Pathophysiology

VHFs are caused by viruses of four distinct families: arenaviruses, filoviruses, bunyaviruses, and flaviviruses. Each of these families share a number of features:

  • They are all RNA viruses, and all are covered, or enveloped, in a fatty (lipid) coating.
  • Their survival is dependent on an animal or insect host, called the natural reservoir.
  • The viruses are geographically restricted to the areas where their host species live.
  • Humans are not the natural reservoir for any of these viruses. Humans are infected when they come into contact with infected hosts. However, with some viruses, after the accidental transmission from the host, humans can transmit the virus to one another.
  • Human cases or outbreaks of hemorrhagic fevers caused by these viruses occur sporadically and irregularly. The occurrence of outbreaks cannot be easily predicted.
  • With a few noteworthy exceptions, there is no cure or established drug treatment for VHFs.
  • In rare cases, other viral and bacterial infections can cause a hemorrhagic fever; scrub typhus is a good example.

Viruses associated with most VHFs are zoonotic. This means that these viruses naturally reside in an animal reservoir host or arthropod vector. They are totally dependent on their hosts for replication and overall survival. For the most part, rodents and arthropods are the main reservoirs for viruses causing VHFs. The multimammate rat, cotton rat, deer mouse, house mouse, and other field rodents are examples of reservoir hosts. Arthropod ticks and mosquitoes serve as vectors for some of the illnesses. However, the hosts of some viruses remain unknown -- Ebola and Marburg viruses are well-known examples.

How are hemorrhagic fever viruses transmitted?

Viruses causing hemorrhagic fever are initially transmitted to humans when the activities of infected reservoir hosts or vectors and humans overlap. The viruses carried in rodent reservoirs are transmitted when humans have contact with urine, fecal matter, saliva, or other body excretions from infected rodents. The viruses associated with arthropod vectors are spread most often when the vector mosquito or tick bites a human, or when a human crushes a tick. However, some of these vectors may spread virus to animals, livestock, for example. Humans then become infected when they care for or slaughter the animals.

Some viruses that cause hemorrhagic fever can spread from one person to another, once an initial person has become infected. Ebola, Marburg, Lassa and Crimean-Congo hemorrhagic fever viruses are examples. This type of secondary transmission of the virus can occur directly, through close contact with infected people or their body fluids. It can also occur indirectly, through contact with objects contaminated with infected body fluids. For example, contaminated syringes and needles have played an important role in spreading infection in outbreaks of Ebola hemorrhagic fever and Lassa fever.

References

http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/vhf.htm

Clinical and treatment aspects

Signs and symptoms of VHFs include (by definition) fever and bleeding diathesis. Manifestations of VHF often also include flushing of the face and chest, petechiae, frank bleeding, edema, hypotension, and shock. Malaise, myalgias, headache, vomiting, and diarrhea occur frequently. Definitive diagnosis is usually made at a reference laboratory with advanced biocontainment capabilities.

Medical management of VHF patients may require intensive supportive care. Antiviral therapy with intravenous ribavirin may be useful in Bunyaviridae and Arenaviridae infections (specifically Lassa fever, RVF, CCHF, and HFRS due to Old World Hantavirus infection) and can be used only under an experimental protocol as a US FDA approved investigational new drug (IND). Convalescent plasma may be effective in Argentine or Bolivian hemorrhagic fevers (also available only as IND). The only licensed vaccine for a VHF is the 17D yellow fever vaccine. Experimental vaccines for other VHFs are not readily available.

Prophylactic (preventive) ribavirin may be effective for some Bunyaviridae and Arenaviridae infections (again, available only as IND).

VHF isolation guidelines dictate that all VHF patients (with the exception of dengue patients) should be cared for using strict contact precautions, including hand hygiene, double gloves, gowns, shoe and leg coverings, and faceshield or goggles. Lassa, CCHF, Ebola, and Marburg viruses may be particularly prone to nosocomial (hospital-based) spread. Airborne precautions should be utilized including, at a minimum, a fit-tested, HEPA filter-equipped respirator (such as an N-95 mask), a battery-powered, air-purifying respirator, or a positive pressure supplied air respirator to be worn by personnel coming within six feet of a VHF patient. Multiple patients should be cohorted (sequestered) to a separate building or a ward with an isolated air-handling system. Environmental decontamination is typically accomplished with hypochlorite or phenolic disinfectants. [1]

Pathophysiology

The diversity of clinical features seen among the VHF infections probably originates from varying mechanisms of pathogenesis. An immunopathogenic mechanism, for example, has been identified for dengue hemorrhagic fever, which usually occurs among patients previously infected with a heterologous dengue serotype. An influential theory explaining this phenomenon is called “antibody-dependent enhancement.” In contrast, disseminated intravascular coagulation (DIC) is thought to underlie the hemorrhagic features of Rift Valley, Marburg and Ebola fevers. In most VHFs, however, the etiology of the coagulopathy is most likely multifactorial (e.g., hepatic damage, consumptive coagulopathy, primary marrow dysfunction, etc).

The reasons for variation among patients infected with the same virus are unknown but stem from a complex system of virus-host interactions. Moreover, why some infected persons develop full-blown VHF while others do not also remains an unresolved issue. Virulence of the infecting agent clearly plays an important role. The “VHF syndrome” (capillary leak, bleeding diathesis and hemodynamic compromise leading to shock) occurs in a majority of patients manifesting disease from filoviruses, CCHF and the South American hemorrhagic fever viruses, while it occurs in a small minority of patients with dengue, RVF and Lassa fever.

Biowarfare/bioterrorism potential

The VHF viruses are spread in a variety of ways. Some may be transmitted to humans through a respiratory route. Although evidence for a history of “weaponization” (development into a biological weapon) does not exist for many of these viruses, all are considered by military medical planners to have a potential for aerosol dissemination, weaponization, or likelihood for confusion with similar agents that might be weaponized. [2]

Notable VHF outbreaks

See also

Sources

  1. Woods, Lt Col Jon B. (ed.) (April 2005). USAMRIID’s Medical Management of Biological Casualties Handbook (6th ed. ed.). U.S. Army Medical Institute of Infectious Diseases, Fort Detrick, Maryland. pp. 143–144. External link in |title= (help)
  2. Woods, Op. cit., pg 145.
  3. "Black Death did not kill indiscriminately." January 29, 2008, Will Dunham. Reuters.
  • Health Protection Agency
  • This article includes information that originally came from US Government publications and websites and is in the public domain.

Template:Viral diseases

de:Hämorrhagisches Fieber eu:Sukar hemorragiko sl:Virusna hemoragična mrzlica fi:Verenvuotokuume sv:Blödarfeber

Template:WH Template:WS Template:Jb1